PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.

@article{Crafton2016PARPIA,
  title={PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.},
  author={Sarah M Crafton and Kristin Bixel and John L. Hays},
  journal={Gynecologic oncology},
  year={2016},
  volume={142 3},
  pages={588-96}
}
The poly (ADP-ribose) polymerase (PARP) family of enzymes is important in several DNA repair pathways. Drugs that inhibit these enzymes have been investigated in many types of cancer, but their application in the treatment of gynecologic malignancies has rapidly evolved - as manifested by the 2014 FDA approval for olaparib in the treatment of recurrent ovarian cancer associated with a germline BRCA mutation (gBRCA). In efforts to broaden their efficacy, current clinical trials have demonstrated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Functions of PARylation in DNA Damage Repair Pathways

Genomics, Proteomics & Bioinformatics • 2016
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…